Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy
Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy
复制标题
DOI：
10.1016/s0360-3016(02)03752-5
复制
发表时间：
2002-12-01
影响因子：
7
通讯作者：
de Torres, I
中科院分区：
文献类型：
--
作者：
Giralt, J;Eraso, A;de Torres, I
目的：表皮生长因子受体（EGFR）在50%-70%的结直肠癌中表达，与预后不良有关。本研究的目的是确定局部进展期直肠癌的EGFR表达率，并分析EGFR表达是否预示肿瘤对术前放疗的反应。方法和材料：1997年12月至2000年10月，45例患者被纳入。治疗包括术前盆腔放疗，21例患者，2个疗程的5-氟尿嘧啶亚叶酸。术后4-8周行手术切除。EGFR的免疫组化测定在放射前诊断活检和切除标本。使用EGFR单克隆抗体（Biogenex，MU 207-UC）进行免疫染色。免疫组化染色根据范围和强度进行评价。我们定义阳性染色（EGFR+）为5%或以上的扩展。结果：术前治疗导致病理完全缓解7例（15%），13例（29%），在25例（56%）无反应。在45个肿瘤中的29个（64%）中观察到EGFR+，并且与临床肿瘤分期和临床淋巴结分期均不相关。EGFR+患者的总体缓解率为34%，EGFR-患者为62%（p = 0.07）。7例病理完全缓解患者中仅1例为EGFR+（p = 0.003）。结论：EGFR在相当数量的局部进展期直肠肿瘤中表达。EGFR表达是晚期直肠癌术前放疗反应不良的指标。(C)2002年爱思唯尔科技有限公司
Purpose: Epidermal growth factor receptor (EGFR) expression is observed in 50%-70% of colorectal carcinomas and is associated with poor prognosis. The aim of this study was to determine the EGFR expression rate in locally advanced rectal cancer and to analyze whether EGFR expression predicts tumor response to preoperative radiotherapy.Methods and Materials: Between December 1997 and October 2000, 45 patients were included. Treatment consisted of preoperative pelvic radiotherapy and, in 21 patients, 2 courses of 5-fluorouracil leucovorin. Surgical resection was performed 4-8 weeks later. Immunohistochernistry for EGFR was determined at the preradiation diagnostic biopsy and in the resected specimens. Immunostaining was performed using EGFR monoclonal antibody (Biogenex, MU 207-UC). Immunohistochemical staining was evaluated according to extension and intensity. We defined positive staining (EGFR+) as extension of 5% or more.Results: Preoperative treatment resulted in pathologic complete remission in 7 patients (15%), downstaging in 13 patients (29%), and no response in 25 patients (56%). EGFR+ was observed in 29 of 45 tumors (64%) and was associated with neither clinical tumor stage nor clinical nodal stage. The overall response rate was 34% in EGFR+ patients vs. 62% in those who were EGFR- (p = 0.07). Only 1 of the 7 pathologic complete remission patients was EGFR+ (p = 0.003).Conclusions: EGFR is expressed in a significant number of locally advanced rectal tumors. EGFR expression is an indicator for poor response to preoperative radiotherapy in advanced rectal carcinoma. (C) 2002 Elsevier Science Inc.